DocCheck AG (AJ91) AI Stock Analysis

• Market Cap: €64.43M
• Dividend Yield: 5.62%
• Average Volume (3M): 1.07K
• Price to Earnings (P/E): 12.3
• Beta (1Y): 0.65
• Revenue Growth: 0.69%
• EPS Growth: 132.12%
• Country: DE
• Employees: 373
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.67
• Shares Outstanding: 5,033,876
• 10 Day Avg. Volume: 791
• 30 Day Avg. Volume: 1,066
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €13.00
• Price Target Upside: 1.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 72 Outperform
• Price Target: €13.00 ▲(1.56% Upside)

DocCheck AG's overall stock score is driven by its strong financial performance and attractive valuation. The company's solid profitability and efficient cash flow management are significant strengths. However, technical indicators suggest a bearish short-term trend, which slightly offsets the positive valuation metrics.

DocCheck AG Business Overview & Revenue Model

Company Description

DocCheck AG is a leading provider of online services for healthcare professionals, primarily operating in the medical and pharmaceutical sectors. The company specializes in creating digital platforms that facilitate communication and information exchange among healthcare providers. Its core products include professional networking tools, medical content, and marketing solutions tailored for the healthcare industry. DocCheck AG also operates a secure online community where healthcare professionals can access and share knowledge, ultimately enhancing their practice and patient care.

How the Company Makes Money

DocCheck AG generates revenue through multiple streams, primarily from subscription fees, advertising, and partnerships with pharmaceutical companies. The company's subscription model allows healthcare professionals to access premium content and tools, creating a steady income source. Additionally, DocCheck earns revenue from targeted advertising aimed at its professional audience, leveraging its extensive user base to attract advertisers within the healthcare sector. Strategic partnerships with pharmaceutical companies further bolster its revenue, as these partnerships often involve co-branded initiatives, sponsored content, and marketing campaigns that align with the interests of healthcare providers. Overall, DocCheck's diversified revenue model ensures its financial stability and growth within the competitive online healthcare space.

DocCheck AG Financial Statement Overview

Summary

DocCheck AG displays a solid financial performance with strong profitability and efficient cash flow management. It maintains a prudent balance sheet with low leverage, although declining revenue and assets pose potential challenges.

Income Statement

DocCheck AG's income statement shows strong profitability with a gross profit margin of 19.6% and a net profit margin of 9.8% for the latest annual period. Revenue growth has been relatively stable, with a modest increase of 0.7% from the previous year. The EBIT margin improved substantially to 12.0% from 6.6%, indicating enhanced operational efficiency. However, there is a concern over the company's declining total revenue over the last few years, which may impact future profitability.

Balance Sheet

The balance sheet of DocCheck AG reflects a solid financial position with a low debt-to-equity ratio of 0.12, suggesting conservative leverage. The equity ratio stands at 65.9%, indicating a strong equity base relative to total assets. Return on equity is healthy at 13.2%, showcasing efficient use of equity capital. However, declining total assets and stockholders' equity in recent periods may pose potential risks to long-term financial stability.

Cash Flow

The cash flow statement highlights a robust operating cash flow to net income ratio of 1.48, demonstrating strong cash generation relative to net income. Free cash flow increased by 21.3% year-over-year, reflecting effective cash management. The company maintains a positive free cash flow to net income ratio of 1.29, underscoring its ability to generate surplus cash after capital expenditures. Nevertheless, fluctuations in free cash flow over recent years warrant monitoring.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	53.79M	53.41M	60.90M	85.92M	63.10M
Gross Profit	10.53M	12.97M	14.08M	21.54M	18.26M
EBITDA	10.18M	9.38M	13.38M	20.09M	15.90M
Net Income	5.28M	2.27M	6.29M	11.40M	9.20M
Balance Sheet
Total Assets	60.86M	56.14M	63.28M	60.25M	46.99M
Cash, Cash Equivalents and Short-Term Investments	21.02M	17.52M	15.66M	21.52M	19.99M
Total Debt	5.01M	5.85M	7.07M	7.03M	1.61M
Total Liabilities	20.78M	18.11M	23.86M	22.08M	15.64M
Stockholders Equity	40.08M	37.33M	38.57M	37.31M	30.91M
Cash Flow
Free Cash Flow	6.82M	5.62M	-557.91K	6.90M	9.15M
Operating Cash Flow	7.82M	7.51M	5.89M	10.92M	12.57M
Investing Cash Flow	-1.65M	-2.02M	-4.92M	-4.39M	-936.57K
Financing Cash Flow	-3.50M	-4.54M	-5.81M	-5.86M	-1.08M

DocCheck AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AJ91, the sentiment is Positive. The current price of 12.8 is above the 20-day moving average (MA) of 12.69, above the 50-day MA of 12.28, and above the 200-day MA of 10.51, indicating a bullish trend. The MACD of 0.20 indicates Positive momentum. The RSI at 59.06 is Neutral, neither overbought nor oversold. The STOCH value of 19.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:AJ91.

DocCheck AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	80 Outperform	45.86M	10.66	―	3.77%	-5.72%	-25.19%
AJ91	72 Outperform	€64.43M	12.29	13.65%	5.62%	0.69%	132.12%
NXU	68 Neutral	1.24B	36.24	11.64%	0.32%	6.72%	33.84%
COP	67 Neutral	1.26B	67.46	5.34%	0.21%	1.16%	-43.53%
V3V	50 Neutral	100.23M	-10.08	-75.65%	―	11.30%	-3316.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%